Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Trading Update

31 Jan 2012 14:00

RNS Number : 4971W
Byotrol PLC
31 January 2012
 



 

31 January 2012

 

 

Byotrol plc

Commercial and Trading Update including

Rentokil Initial UltraProtect™ product launch and extension of agreement with Fortune 150 partner

 

 

Byotrol plc ('Byotrol' or the "Company"), the developer of anti microbial hygiene technologies, is pleased to provide a commercial and trading update.

 

Following an extensive development process by partners Byotrol and Rentokil Initial plc ('Rentokil Initial'), Rentokil Initial last week formally launched the UltraProtect™ range, powered by Byotrol, under the contract announced in July 2011. UltraProtect™ is a range of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes. 

 

Rentokil Initial is one of the largest business services companies in the world, operating in the major economies of Europe, North America, Asia Pacific and Africa. Plans are underway to introduce UltraProtect™ across Europe in 2012. It is expected that the new revolutionary sanitiser will be available in more than ten countries - beginning with the UK and then France and Germany in the coming weeks. This exclusive range of products will target a number of key markets including the commercial, medical, hospitality & leisure and education sectors. 

 

Peter Slator, Divisional Managing Director at Rentokil Initial commented:

 

"Our new range of surface and hand hygiene products, powered by Byotrol's unique technology, will be a valuable element in achieving Initial's objective of 'Raising Hygiene Standards' throughout our customers' organisations. It will give our customers access to a pioneering hygiene solution and enable us to penetrate new markets."

 

 

In addition, through Byotrol Consumer Products Limited ('BCP'), Byotrol is pleased to announce that it has agreed terms for a six month extension of the Joint Development Agreement ('JDA') with their Fortune 150 partner company, for which BCP will receive $300,000. This follows the successful completion of all technical milestones and the successful assessment of Byotrol's technology performance in the plan referred to in the JDA announced in May 2011. The two companies will now complete consumer research and commercial analysis with the aim of a decision on a full commercial agreement.

 

The Board of Byotrol is pleased to report these significant commercial developments achieved within the last six months, which are transforming Byotrol into a better quality, more sustainable, business. There have, however, been some delays in anticipated launch dates, and additional investment of development time, as Byotrol seeks to maximise its potential margins and focus on better quality, more repeatable business. These delays will have an impact on the results for the financial year ending 31 March 2012. Revenue for the 12 months to 31 March 2012 is now expected to be approximately £2.0m with a consequent effect on the trading loss for the year.

 

The Company anticipates having cash of £1.2m at 31 March 2012 and still expects to be trading profitably by the year ending 31 March 2013.

 

Commenting on the current developments, Gary Millar, CEO of Byotrol, said:

 

"Byotrol is at a very exciting phase in its development. In particular the launch of UltraProtect™ is tremendously positive and will demonstrate the breadth of success that Byotrol products can achieve through partnering with established industry suppliers with global reach. We will continue to work actively on our long term relationship with Rentokil Initial, in addition to other selected partners, to achieve a rapid increase in our market penetration.

 

"I am also delighted that we have successfully achieved all the technical milestones envisaged with our Fortune 150 consumer products partner and look forward to the extension of our joint development agreement.

 

"The complex nature of the projects involved in generating more repeatable, better quality revenues, has resulted in some delays in expected launch dates and as a result our revenues for the 12 months to 31 March 2012 will be lower than expected. I am confident that we now have a better quality business with strong partners that will lead to sustained growth for the future."

 

 

Enquiries:

 

Byotrol plc

Gary Millar - Chief Executive

Richard Bell - Finance Director

 

finnCap

Geoff Nash/Christopher Raggett - Corporate Finance

Tom Jenkins/Simon Starr - Corporate Broking

 

Winningtons

Tom Cooper/Paul Vann

01925 742 000

 

 

 

020 7220 0500

 

 

020 3176 4722

0797 122 1972

tom.cooper@winningtons.co.uk

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a standalone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTXFLFXLFFXBBF
Date   Source Headline
5th Sep 20077:01 amRNSDirector/PDMR Shareholding
4th Sep 20077:00 amRNSDirectorate Change
31st Aug 200710:07 amRNSTotal Voting Rights
16th Aug 20078:41 amRNSAIM RULE 26 INFORMATION
6th Aug 20072:49 pmRNSAdditional Listing
1st Aug 20078:21 amRNSTotal Voting Rights
1st Aug 20077:01 amRNSDirector/PDMR Shareholding
30th Jul 20071:04 pmRNSAGM Statement
30th Jul 20077:01 amRNSJoint Venture
20th Jun 20077:01 amRNSAnnual Report and Accounts
8th Jun 20077:00 amRNSAdditional Listing
4th Jun 20077:00 amRNSNEW GLOBAL CONTRACT
4th May 20077:01 amBUSBYOTROL plc • HEALTHCARE PRODUCT LAUNCH
18th Apr 20077:45 amRNSTrading Statement
30th Mar 20079:24 amRNSTotal Voting Rights
22nd Mar 20072:47 pmRNSHolding(s) in Company
19th Mar 20079:56 amRNSHolding(s) in Company
19th Mar 20079:52 amRNSHolding(s) in Company
19th Mar 20079:51 amRNSHolding(s) in Company
19th Mar 20079:49 amRNSHolding(s) in Company
13th Mar 20073:28 pmRNSAdditional Listing
28th Feb 20071:04 pmRNSTotal Voting Rights
23rd Feb 20077:01 amRNSAdditional Listing
21st Feb 20077:01 amRNSDirector/PDMR Shareholding
8th Feb 20073:54 pmRNSAdditional Listing
5th Feb 20072:52 pmRNSHolding(s) in Company
19th Jan 20072:30 pmRNSTotal Voting Rights
12th Jan 20073:07 pmRNSIssue of Equity
14th Dec 20065:00 pmRNSTotal Voting Rights
11th Dec 20067:00 amRNSInterim Results
27th Nov 20069:32 amRNSBoard Appointment
14th Nov 20067:03 amRNSSynergy Healthcare Agreement
1st Nov 20067:01 amRNSIssue of Equity
26th Oct 20061:12 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 20061:02 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200612:28 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200610:24 amRNSDistribution Agreements
16th Oct 20067:01 amBUSByotrol Plc: Result of Byotrol Use in Hospital
18th Sep 200610:56 amBUSREPEAT: Byotrol Plc: Chinese Patent Granted and Customer Orders Shipped
18th Sep 200610:30 amBUSByotrol Plc: Chinese Patent Granted and Customer Orders Shipped
11th Sep 20067:01 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.